Evommune, Inc. 8K

Evommune, Inc. initiated and dosed the first patient in a global Phase 2b trial of its oral MRGPRX2 inhibitor EVO756 for migraine prophylaxis, with top-line results anticipated in 2027.

On July 30, 2026, Evommune, Inc. announced that it has dosed the first patient in a global Phase 2b randomized, double-blind, placebo-controlled, dose-ranging clinical trial of EVO756, a first-in-class, potent and highly selective oral MRGPRX2 antagonist, for the prophylactic treatment of refractory migraine in adults experiencing six or more migraine days per month, with approximately 330 patients to receive up to 100 mg daily for 12 weeks and top-line data expected in 2027; the study’s primary endpoint is change from baseline in monthly migraine days, with key secondary and exploratory endpoints assessing responder rates, headache days, acute medication use, biomarkers, and quality of life, reflecting Evommune’s strategy to develop differentiated oral therapies targeting chronic inflammatory diseases including migraine and atopic dermatitis.

Filing Facts

CIK

2044725

Ticker

-

Form

8K

Source Type

sec

Accession

0001193125-26-324972

Alert Tier

6